Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic
Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients. We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patient...
Gespeichert in:
| Veröffentlicht in: | Respiratory investigation 2020-11, Vol.58 (6), p.437-439 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 439 |
|---|---|
| container_issue | 6 |
| container_start_page | 437 |
| container_title | Respiratory investigation |
| container_volume | 58 |
| creator | Guiot, J. Henket, M. Frix, A.N. Delvaux, M. Denis, A. Giltay, L. Thys, M. Gester, F. Moutschen, M. Corhay, J.L. Louis, R. Ancion, A. Bouquegneau, A. Bovy, C. Darcis, G. Defraigne, J.O. Duysinx, B. Ghuysen, A. Gilbert, A. Heinen, V. Lambermont, B. Malaise, O. Martin, M. Misset, B. Moutschen, M. Nguyen Dang, D. Piazza, J. Szecel, J. Vaillant, F. Van Cauwenberge, H. Von Frenckell, C. Vroonen, L. |
| description | Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients.
We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19.
We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection.
Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19. |
| doi_str_mv | 10.1016/j.resinv.2020.08.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7501770</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2212534520301246</els_id><sourcerecordid>2446672421</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-c6e563f59cdde9d707a85469def8b43eeb9e85c87e55f1ab512b7a5c0724a4313</originalsourceid><addsrcrecordid>eNp9kctu2zAQRYmiRRMk-YMsuOxGCknxIW0KFO4jAQJk0TRbgiJHNg1ZcjmUU_99pTpI0U1nMwNycC55LyHXnJWccX2zLRNgHA6lYIKVrC4Z02_IuRBcFKpS1dvXWaozcoW4ZXNpJSTX78lZJRpTs6Y5J_g9DuseCg9DhkTh1x5ShMEDHTu6d3meM9LnmDc0LhuYY46up_00rGmICA4BaZjSjKF5AxRc6o80uCMuhOVk9fB097ngzYwbAuyivyTvOtcjXL30C_Lj65fH1W1x__DtbvXpvvBSy1x4DUpXnWp8CNAEw4yrldRNgK5uZQXQNlArXxtQquOuVVy0xinPjJBOVry6IB9P3P3U7iAsX0yut_sUdy4d7eii_fdmiBu7Hg_WKMaNYTPgwwsgjT8nwGx3ET30vRtgnNAKKbWe1cSiJU-rPo2ICbpXGc7sEpnd2lNkdonMstrOefx9Isw-HCIki_6P_SEm8NmGMf4f8BtVSKJS</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2446672421</pqid></control><display><type>article</type><title>Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic</title><source>Alma/SFX Local Collection</source><creator>Guiot, J. ; Henket, M. ; Frix, A.N. ; Delvaux, M. ; Denis, A. ; Giltay, L. ; Thys, M. ; Gester, F. ; Moutschen, M. ; Corhay, J.L. ; Louis, R. ; Ancion, A. ; Bouquegneau, A. ; Bovy, C. ; Darcis, G. ; Defraigne, J.O. ; Duysinx, B. ; Ghuysen, A. ; Gilbert, A. ; Heinen, V. ; Lambermont, B. ; Malaise, O. ; Martin, M. ; Misset, B. ; Moutschen, M. ; Nguyen Dang, D. ; Piazza, J. ; Szecel, J. ; Vaillant, F. ; Van Cauwenberge, H. ; Von Frenckell, C. ; Vroonen, L.</creator><creatorcontrib>Guiot, J. ; Henket, M. ; Frix, A.N. ; Delvaux, M. ; Denis, A. ; Giltay, L. ; Thys, M. ; Gester, F. ; Moutschen, M. ; Corhay, J.L. ; Louis, R. ; Ancion, A. ; Bouquegneau, A. ; Bovy, C. ; Darcis, G. ; Defraigne, J.O. ; Duysinx, B. ; Ghuysen, A. ; Gilbert, A. ; Heinen, V. ; Lambermont, B. ; Malaise, O. ; Martin, M. ; Misset, B. ; Moutschen, M. ; Nguyen Dang, D. ; Piazza, J. ; Szecel, J. ; Vaillant, F. ; Van Cauwenberge, H. ; Von Frenckell, C. ; Vroonen, L. ; COVID-19 clinical investigators of the CHU de Liège</creatorcontrib><description>Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients.
We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19.
We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection.
Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19.</description><identifier>ISSN: 2212-5345</identifier><identifier>EISSN: 2212-5353</identifier><identifier>DOI: 10.1016/j.resinv.2020.08.006</identifier><identifier>PMID: 32978099</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Clinical epidemiology ; COVID-19 ; Interstitial lung diseases ; Lung fibrosis ; Rapid Communication</subject><ispartof>Respiratory investigation, 2020-11, Vol.58 (6), p.437-439</ispartof><rights>2020 The Japanese Respiratory Society</rights><rights>2020 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved. 2020 The Japanese Respiratory Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-c6e563f59cdde9d707a85469def8b43eeb9e85c87e55f1ab512b7a5c0724a4313</citedby><cites>FETCH-LOGICAL-c464t-c6e563f59cdde9d707a85469def8b43eeb9e85c87e55f1ab512b7a5c0724a4313</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids></links><search><creatorcontrib>Guiot, J.</creatorcontrib><creatorcontrib>Henket, M.</creatorcontrib><creatorcontrib>Frix, A.N.</creatorcontrib><creatorcontrib>Delvaux, M.</creatorcontrib><creatorcontrib>Denis, A.</creatorcontrib><creatorcontrib>Giltay, L.</creatorcontrib><creatorcontrib>Thys, M.</creatorcontrib><creatorcontrib>Gester, F.</creatorcontrib><creatorcontrib>Moutschen, M.</creatorcontrib><creatorcontrib>Corhay, J.L.</creatorcontrib><creatorcontrib>Louis, R.</creatorcontrib><creatorcontrib>Ancion, A.</creatorcontrib><creatorcontrib>Bouquegneau, A.</creatorcontrib><creatorcontrib>Bovy, C.</creatorcontrib><creatorcontrib>Darcis, G.</creatorcontrib><creatorcontrib>Defraigne, J.O.</creatorcontrib><creatorcontrib>Duysinx, B.</creatorcontrib><creatorcontrib>Ghuysen, A.</creatorcontrib><creatorcontrib>Gilbert, A.</creatorcontrib><creatorcontrib>Heinen, V.</creatorcontrib><creatorcontrib>Lambermont, B.</creatorcontrib><creatorcontrib>Malaise, O.</creatorcontrib><creatorcontrib>Martin, M.</creatorcontrib><creatorcontrib>Misset, B.</creatorcontrib><creatorcontrib>Moutschen, M.</creatorcontrib><creatorcontrib>Nguyen Dang, D.</creatorcontrib><creatorcontrib>Piazza, J.</creatorcontrib><creatorcontrib>Szecel, J.</creatorcontrib><creatorcontrib>Vaillant, F.</creatorcontrib><creatorcontrib>Van Cauwenberge, H.</creatorcontrib><creatorcontrib>Von Frenckell, C.</creatorcontrib><creatorcontrib>Vroonen, L.</creatorcontrib><creatorcontrib>COVID-19 clinical investigators of the CHU de Liège</creatorcontrib><title>Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic</title><title>Respiratory investigation</title><description>Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients.
We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19.
We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection.
Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19.</description><subject>Clinical epidemiology</subject><subject>COVID-19</subject><subject>Interstitial lung diseases</subject><subject>Lung fibrosis</subject><subject>Rapid Communication</subject><issn>2212-5345</issn><issn>2212-5353</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kctu2zAQRYmiRRMk-YMsuOxGCknxIW0KFO4jAQJk0TRbgiJHNg1ZcjmUU_99pTpI0U1nMwNycC55LyHXnJWccX2zLRNgHA6lYIKVrC4Z02_IuRBcFKpS1dvXWaozcoW4ZXNpJSTX78lZJRpTs6Y5J_g9DuseCg9DhkTh1x5ShMEDHTu6d3meM9LnmDc0LhuYY46up_00rGmICA4BaZjSjKF5AxRc6o80uCMuhOVk9fB097ngzYwbAuyivyTvOtcjXL30C_Lj65fH1W1x__DtbvXpvvBSy1x4DUpXnWp8CNAEw4yrldRNgK5uZQXQNlArXxtQquOuVVy0xinPjJBOVry6IB9P3P3U7iAsX0yut_sUdy4d7eii_fdmiBu7Hg_WKMaNYTPgwwsgjT8nwGx3ET30vRtgnNAKKbWe1cSiJU-rPo2ICbpXGc7sEpnd2lNkdonMstrOefx9Isw-HCIki_6P_SEm8NmGMf4f8BtVSKJS</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Guiot, J.</creator><creator>Henket, M.</creator><creator>Frix, A.N.</creator><creator>Delvaux, M.</creator><creator>Denis, A.</creator><creator>Giltay, L.</creator><creator>Thys, M.</creator><creator>Gester, F.</creator><creator>Moutschen, M.</creator><creator>Corhay, J.L.</creator><creator>Louis, R.</creator><creator>Ancion, A.</creator><creator>Bouquegneau, A.</creator><creator>Bovy, C.</creator><creator>Darcis, G.</creator><creator>Defraigne, J.O.</creator><creator>Duysinx, B.</creator><creator>Ghuysen, A.</creator><creator>Gilbert, A.</creator><creator>Heinen, V.</creator><creator>Lambermont, B.</creator><creator>Malaise, O.</creator><creator>Martin, M.</creator><creator>Misset, B.</creator><creator>Moutschen, M.</creator><creator>Nguyen Dang, D.</creator><creator>Piazza, J.</creator><creator>Szecel, J.</creator><creator>Vaillant, F.</creator><creator>Van Cauwenberge, H.</creator><creator>Von Frenckell, C.</creator><creator>Vroonen, L.</creator><general>Elsevier B.V</general><general>The Japanese Respiratory Society. Published by Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20201101</creationdate><title>Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic</title><author>Guiot, J. ; Henket, M. ; Frix, A.N. ; Delvaux, M. ; Denis, A. ; Giltay, L. ; Thys, M. ; Gester, F. ; Moutschen, M. ; Corhay, J.L. ; Louis, R. ; Ancion, A. ; Bouquegneau, A. ; Bovy, C. ; Darcis, G. ; Defraigne, J.O. ; Duysinx, B. ; Ghuysen, A. ; Gilbert, A. ; Heinen, V. ; Lambermont, B. ; Malaise, O. ; Martin, M. ; Misset, B. ; Moutschen, M. ; Nguyen Dang, D. ; Piazza, J. ; Szecel, J. ; Vaillant, F. ; Van Cauwenberge, H. ; Von Frenckell, C. ; Vroonen, L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-c6e563f59cdde9d707a85469def8b43eeb9e85c87e55f1ab512b7a5c0724a4313</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Clinical epidemiology</topic><topic>COVID-19</topic><topic>Interstitial lung diseases</topic><topic>Lung fibrosis</topic><topic>Rapid Communication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guiot, J.</creatorcontrib><creatorcontrib>Henket, M.</creatorcontrib><creatorcontrib>Frix, A.N.</creatorcontrib><creatorcontrib>Delvaux, M.</creatorcontrib><creatorcontrib>Denis, A.</creatorcontrib><creatorcontrib>Giltay, L.</creatorcontrib><creatorcontrib>Thys, M.</creatorcontrib><creatorcontrib>Gester, F.</creatorcontrib><creatorcontrib>Moutschen, M.</creatorcontrib><creatorcontrib>Corhay, J.L.</creatorcontrib><creatorcontrib>Louis, R.</creatorcontrib><creatorcontrib>Ancion, A.</creatorcontrib><creatorcontrib>Bouquegneau, A.</creatorcontrib><creatorcontrib>Bovy, C.</creatorcontrib><creatorcontrib>Darcis, G.</creatorcontrib><creatorcontrib>Defraigne, J.O.</creatorcontrib><creatorcontrib>Duysinx, B.</creatorcontrib><creatorcontrib>Ghuysen, A.</creatorcontrib><creatorcontrib>Gilbert, A.</creatorcontrib><creatorcontrib>Heinen, V.</creatorcontrib><creatorcontrib>Lambermont, B.</creatorcontrib><creatorcontrib>Malaise, O.</creatorcontrib><creatorcontrib>Martin, M.</creatorcontrib><creatorcontrib>Misset, B.</creatorcontrib><creatorcontrib>Moutschen, M.</creatorcontrib><creatorcontrib>Nguyen Dang, D.</creatorcontrib><creatorcontrib>Piazza, J.</creatorcontrib><creatorcontrib>Szecel, J.</creatorcontrib><creatorcontrib>Vaillant, F.</creatorcontrib><creatorcontrib>Van Cauwenberge, H.</creatorcontrib><creatorcontrib>Von Frenckell, C.</creatorcontrib><creatorcontrib>Vroonen, L.</creatorcontrib><creatorcontrib>COVID-19 clinical investigators of the CHU de Liège</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Respiratory investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guiot, J.</au><au>Henket, M.</au><au>Frix, A.N.</au><au>Delvaux, M.</au><au>Denis, A.</au><au>Giltay, L.</au><au>Thys, M.</au><au>Gester, F.</au><au>Moutschen, M.</au><au>Corhay, J.L.</au><au>Louis, R.</au><au>Ancion, A.</au><au>Bouquegneau, A.</au><au>Bovy, C.</au><au>Darcis, G.</au><au>Defraigne, J.O.</au><au>Duysinx, B.</au><au>Ghuysen, A.</au><au>Gilbert, A.</au><au>Heinen, V.</au><au>Lambermont, B.</au><au>Malaise, O.</au><au>Martin, M.</au><au>Misset, B.</au><au>Moutschen, M.</au><au>Nguyen Dang, D.</au><au>Piazza, J.</au><au>Szecel, J.</au><au>Vaillant, F.</au><au>Van Cauwenberge, H.</au><au>Von Frenckell, C.</au><au>Vroonen, L.</au><aucorp>COVID-19 clinical investigators of the CHU de Liège</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic</atitle><jtitle>Respiratory investigation</jtitle><date>2020-11-01</date><risdate>2020</risdate><volume>58</volume><issue>6</issue><spage>437</spage><epage>439</epage><pages>437-439</pages><issn>2212-5345</issn><eissn>2212-5353</eissn><abstract>Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients.
We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19.
We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection.
Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19.</abstract><pub>Elsevier B.V</pub><pmid>32978099</pmid><doi>10.1016/j.resinv.2020.08.006</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2212-5345 |
| ispartof | Respiratory investigation, 2020-11, Vol.58 (6), p.437-439 |
| issn | 2212-5345 2212-5353 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7501770 |
| source | Alma/SFX Local Collection |
| subjects | Clinical epidemiology COVID-19 Interstitial lung diseases Lung fibrosis Rapid Communication |
| title | Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A24%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Single-center%20experience%20of%20patients%20with%20interstitial%20lung%20diseases%20during%20the%20early%20days%20of%20the%20COVID-19%20pandemic&rft.jtitle=Respiratory%20investigation&rft.au=Guiot,%20J.&rft.aucorp=COVID-19%20clinical%20investigators%20of%20the%20CHU%20de%20Li%C3%A8ge&rft.date=2020-11-01&rft.volume=58&rft.issue=6&rft.spage=437&rft.epage=439&rft.pages=437-439&rft.issn=2212-5345&rft.eissn=2212-5353&rft_id=info:doi/10.1016/j.resinv.2020.08.006&rft_dat=%3Cproquest_pubme%3E2446672421%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2446672421&rft_id=info:pmid/32978099&rft_els_id=S2212534520301246&rfr_iscdi=true |